What is the role of minimally invasive surgical treatments for benign prostatic enlargement?

Franco, Juan Víctor Ariel; Jung, Jae Hung; Liquitay, Camila Micaela Escobar; Dahm, Philipp

doi:10.1136/bmj-2021-069002

Cited by 2 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…External stakeholders highlighted the need for reviews on minimally invasive treatments and desmopressin for lower urinary tract symptoms, for which there is a suite of Cochrane reviews [20,[22][23][24][25][26]. The CRG strategy for dissemination was co-publication of those reviews [22,[27][28][29], which has been shown to improve the impact of Cochrane reviews by reaching a highly specialized readership [30]. Moreover, both reviews have been cited in clinical practice guidelines.…”

Section: Final Editorial Prioritizationmentioning

confidence: 99%

Quick prioritization of Cochrane reviews on benign conditions of the prostate

Franco

Jung

Dahm

2023

Cochrane Evidence Synthesis and Methods

Self Cite

View full text Add to dashboard Cite

Introduction: Benign conditions of the prostate include benign prostatic enlargement and prostatitis, which constitute an important cause of morbidity in men.Objective: We aimed to generate a list of priority topics of interest to our external stakeholders within our editorial scope.Methods: Following Cochrane's guidance, we developed a tiered approach for consulting internal and external stakeholders, including members from Urological societies. First, we analyzed our portfolio, including different impact measurements, to assess the need for updates. Then, following criteria related to the feasibility, novelty and relevance of prospective topics for evidence synthesis, we narrowed the list to a suite of titles for updates or new reviews.Results: Twelve editors provided initial feedback as to what the priorities were for updating existing reviews and for new reviews in our portfolio. The editors identified gaps in our portfolio, mainly covering new treatments for benign prostatic hyperplasia. Then we consulted external stakeholders obtaining 30 responses from 14 countries. These stakeholders provided additional information about the relative importance of existing topics and suggested new ones. We identified that many of the latter were already covered in our portfolio, highlighting gaps in their dissemination. Finally, we narrowed down four priority topics that the editorial group will take forward and two additional topics that might need other considerations before being commissioned.Conclusions: Following Cochrane's guidance on priority setting, we identified topics relevant to our editors and external stakeholders by analysing our portfolio and two rounds of surveys. Moreover, we identified opportunities for disseminating existing reviews. Further evaluation is needed of the following up commissioning process for priority reviews.

show abstract